FORGRELIS Trademark

Trademark Overview

On Tuesday, December 19, 2006, a trademark application was filed for FORGRELIS with the United States Patent and Trademark Office. The USPTO has given the FORGRELIS trademark a serial number of 79035051. The federal status of this trademark filing is IR CANCELLED - US REGISTRATION CANCELLED as of Monday, December 19, 2016. This trademark is owned by AstraZeneca AB. The FORGRELIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of oncological disorders, cardiovascular diseases, respiratory diseases, inflammation/infection, gastrointestinal diseases and central nervous system diseases
forgrelis

General Information

Serial Number79035051
Word MarkFORGRELIS
Filing DateTuesday, December 19, 2006
Status404 - IR CANCELLED - US REGISTRATION CANCELLED
Status DateMonday, December 19, 2016
Registration Number3398743
Registration DateTuesday, March 18, 2008
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 1, 2008

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment and prevention of oncological disorders, cardiovascular diseases, respiratory diseases, inflammation/infection, gastrointestinal diseases and central nervous system diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, October 24, 2014
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAstraZeneca AB
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressSE
Party NameAstraZeneca AB
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressSE
Party NameAstraZeneca AB
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressSE

Trademark Events

Event DateEvent Description
Friday, July 14, 2017NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Friday, July 14, 2017DEATH OF INTERNATIONAL REGISTRATION
Friday, September 4, 2015TOTAL INVALIDATION PROCESSED BY THE IB
Monday, August 17, 2015TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Monday, August 17, 2015INVALIDATION PROCESSED
Wednesday, June 24, 2015TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, October 24, 2014CANCELLED SECTION 71
Friday, January 1, 2010FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, June 24, 2008FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, June 24, 2008FINAL DISPOSITION PROCESSED
Wednesday, June 18, 2008FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, March 18, 2008REGISTERED-PRINCIPAL REGISTER
Tuesday, January 1, 2008PUBLISHED FOR OPPOSITION
Wednesday, December 12, 2007NOTICE OF PUBLICATION
Saturday, November 24, 2007LAW OFFICE PUBLICATION REVIEW COMPLETED
Saturday, November 24, 2007ASSIGNED TO LIE
Saturday, October 20, 2007APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, October 18, 2007TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 18, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 18, 2007TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, June 17, 2007ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, June 17, 2007TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, May 3, 2007REFUSAL PROCESSED BY IB
Wednesday, April 18, 2007NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, April 18, 2007REFUSAL PROCESSED BY MPU
Wednesday, April 18, 2007NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, April 17, 2007NON-FINAL ACTION WRITTEN
Thursday, April 12, 2007ASSIGNED TO EXAMINER
Friday, March 23, 2007NEW APPLICATION ENTERED IN TRAM
Thursday, March 22, 2007SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

forgrelis diseases infection inflammation gastrointestinal central system nervous respiratory pharmaceutical prevention